1[1]Hans RB. The new angiotensin Ⅱ receptor antagonist, irbesartanpharmacokinetic and pharmacodynamic considerations [J]. Am JHypertens, 1997,10(12): S311 - S317.
2[2]Cazaubon C, Gougat J,Bousquet F, et al. Pharmacological characterization of SR47436, a new nonpeptide AT1 subtype angiotensinⅡ receptor antagonist[J]. J Pharmacol Exp Ther, 1993,265:S826 - S834.
3[3]Pierre L, John MF. Effects and tolerability of irbesartan versusenalapril in patients with severe hypertension[J]. Am J Cardiol,1997,80(15): 1613 - 1615.
4[4]Richard AR, Chen-sheng Lin. Dose-related efficacy of irbesartanfor hypertension an integrated analysis[J]. Hypertension, 1998,31(6): 1311 - 1316.
5[5]James LP, Robort MG, Thomas WL, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderatehypertension[J]. Am J Hypertens, 1998,11 (4): 462 - 470.
6[6]Oparil S, Guthrie R, Lewin AJ, et al. A elective-titration study ofthe comparative effectiveness of two angiotension Ⅱ receptorblockers, Irbesartan and Losartan[J]. Clin Ther, 1998,20(12):398 - 409.
8[2]Holwerda NJ,Fogari R,Angeli P,et al.Valsartan,a new angiotensin Ⅱ antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril[J].J Hypertens,1996,4(9)∶1147-1151.
9[3]Grosse-Heitmeyer W,Rochner-Zamgiavadi A.Effect of 80mg valsartan 1 and 5 weeks after onset of therapy in patients with mild essential hypertension[J].Clin Pharmacol (D),1997,52(2)∶A12.
10[4]Benz J,Oshrain C,Henry V,et al.Valsartan,a new angiotensin Ⅱ receptor antagonist:a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide[J].J Clin Pharmacol,1997,37∶101-107.
